PURPOSE: We previously showed that overexpression of epidermal growth factor receptor (EGFR) is associated with malignant grade in childhood glioma. The objective of this study was to determine whether protein expression of EGFR or platelet-derived growth factor receptor (PDGFR) and their active signaling pathways are related to malignant histology, progression of disease, and worse survival. EXPERIMENTAL DESIGN: Tissue microarrays were prepared from untreated tumors from 85 new glioma patients [22 high-grade gliomas (HGG) and 63 low-grade gliomas (LGG)] diagnosed at this institution from 1989 to 2004. Immunohistochemistry was used to assess total expression of EGFR, PDGFR beta, and PTEN and expression of phosphorylated EGFR, phosphorylated PDGFR alpha (p-PDGFR alpha), phosphorylated AKT, phosphorylated mitogen-activated protein kinase, and phosphorylated mammalian target of rapamycin. These results were correlated with clinicopathologic data, including extent of initial tumor resection, evidence of dissemination, tumor grade, proliferation index, and survival, as well as with Affymetrix gene expression profiles previously obtained from a subset of these tumors. RESULTS: High expression of p-PDGFR alpha, EGFR, PDGFR beta, and phosphorylated EGFR was seen in 85.7%, 80.0%, 78.9%, and 47.4% of HGG and 40.0%, 87.1%, 41.7%, and 30.6% of LGG, respectively. However, high expression of p-PDGFR alpha and PDGFR beta was the only significant association with malignant histology (P = 0.031 and 0.005, respectively); only the loss of PTEN expression was associated with worse overall survival. None of these targets, either alone or in combination, was significantly associated with progression-free survival in either LGG or HGG. CONCLUSIONS: High PDGFR protein expression is significantly associated with malignant histology in pediatric gliomas, but it does not represent an independent prognostic factor. Deficient PTEN expression is associated with worse overall survival in HGG.
PURPOSE: We previously showed that overexpression of epidermal growth factor receptor (EGFR) is associated with malignant grade in childhood glioma. The objective of this study was to determine whether protein expression of EGFR or platelet-derived growth factor receptor (PDGFR) and their active signaling pathways are related to malignant histology, progression of disease, and worse survival. EXPERIMENTAL DESIGN: Tissue microarrays were prepared from untreated tumors from 85 new gliomapatients [22 high-grade gliomas (HGG) and 63 low-grade gliomas (LGG)] diagnosed at this institution from 1989 to 2004. Immunohistochemistry was used to assess total expression of EGFR, PDGFR beta, and PTEN and expression of phosphorylated EGFR, phosphorylated PDGFR alpha (p-PDGFR alpha), phosphorylated AKT, phosphorylated mitogen-activated protein kinase, and phosphorylated mammalian target of rapamycin. These results were correlated with clinicopathologic data, including extent of initial tumor resection, evidence of dissemination, tumor grade, proliferation index, and survival, as well as with Affymetrix gene expression profiles previously obtained from a subset of these tumors. RESULTS: High expression of p-PDGFR alpha, EGFR, PDGFR beta, and phosphorylated EGFR was seen in 85.7%, 80.0%, 78.9%, and 47.4% of HGG and 40.0%, 87.1%, 41.7%, and 30.6% of LGG, respectively. However, high expression of p-PDGFR alpha and PDGFR beta was the only significant association with malignant histology (P = 0.031 and 0.005, respectively); only the loss of PTEN expression was associated with worse overall survival. None of these targets, either alone or in combination, was significantly associated with progression-free survival in either LGG or HGG. CONCLUSIONS: High PDGFR protein expression is significantly associated with malignant histology in pediatric gliomas, but it does not represent an independent prognostic factor. Deficient PTEN expression is associated with worse overall survival in HGG.
Authors: David A Reardon; Merrill J Egorin; Jennifer A Quinn; Jeremy N Rich; Jeremy N Rich; Sridharan Gururangan; Idharan Gururangan; James J Vredenburgh; Annick Desjardins; Sith Sathornsumetee; James M Provenzale; James E Herndon; Jeannette M Dowell; Michael A Badruddoja; Roger E McLendon; Theodore F Lagattuta; Kimberly P Kicielinski; Gregor Dresemann; John H Sampson; Allan H Friedman; August J Salvado; Henry S Friedman Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: E Galanis; J Buckner; D Kimmel; R Jenkins; B Alderete; J O'Fallon; C H Wang; B W Scheithauer; C D James Journal: Int J Oncol Date: 1998-10 Impact factor: 5.650
Authors: Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay Journal: J Neurosurg Date: 2006-11 Impact factor: 5.115
Authors: Tobey J MacDonald; Edward B Arenson; Joann Ater; Richard Sposto; Herbert E Bevan; Janet Bruner; Melvin Deutsch; Elizabeth Kurczynski; Thomas Luerssen; Patricia McGuire-Cullen; Richard O'Brien; Narayan Shah; Paul Steinbok; John Strain; John Thomson; Emi Holmes; Gilbert Vezina; Allan Yates; Peter Phillips; Roger Packer Journal: Cancer Date: 2005-12-15 Impact factor: 6.860
Authors: Ian F Pollack; Regina I Jakacki; Susan M Blaney; Michael L Hancock; Mark W Kieran; Peter Phillips; Larry E Kun; Henry Friedman; Roger Packer; Anu Banerjee; J Russell Geyer; Stewart Goldman; Tina Young Poussaint; Matthew J Krasin; Yanfeng Wang; Michael Hayes; Anthony Murgo; Susan Weiner; James M Boyett Journal: Neuro Oncol Date: 2007-02-09 Impact factor: 12.300
Authors: Amy B Heimberger; Roman Hlatky; Dima Suki; David Yang; Jeff Weinberg; Mark Gilbert; Raymond Sawaya; Kenneth Aldape Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich Journal: Genes Dev Date: 2012-06-01 Impact factor: 11.361
Authors: Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger Journal: Clin Cancer Res Date: 2010-10-04 Impact factor: 12.531
Authors: Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader Journal: J Neurooncol Date: 2011-07-01 Impact factor: 4.130
Authors: Sven R Kantelhardt; Wouter Caarls; Anthony H B de Vries; Guy M Hagen; Thomas M Jovin; Walter Schulz-Schaeffer; Veit Rohde; Alf Giese; Donna J Arndt-Jovin Journal: PLoS One Date: 2010-06-30 Impact factor: 3.240
Authors: O Martinho; A Longatto-Filho; M B K Lambros; A Martins; C Pinheiro; A Silva; F Pardal; J Amorim; A Mackay; F Milanezi; N Tamber; K Fenwick; A Ashworth; J S Reis-Filho; J M Lopes; R M Reis Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640